No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer

Anticancer Res. 2016 Sep;36(9):4965-70. doi: 10.21873/anticanres.11065.

Abstract

Aim: The renin-angiotensin system (RAS) was investigated as a target for cancer treatment.

Patients and methods: A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored.

Results: The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified.

Conclusion: No survival benefit from ASIs was observed in BTC.

Keywords: Angiotensin system inhibitor; biliary tract cancer; chemotherapy; renin-angiotensin system.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
  • Biliary Tract Neoplasms / drug therapy*
  • Biliary Tract Neoplasms / pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Renin-Angiotensin System / drug effects*
  • Treatment Outcome

Substances

  • Angiotensin-Converting Enzyme Inhibitors